«We know that 70 - 75
percent of glioblastoma patients undergo surgery for tumor debulking, and we have previously shown that MSCs encapsulated in biocompatible gels can be used as therapeutic agents in a mouse model that mimics this debulking,» he continued.
Using data from The Cancer Genome Atlas (TCGA), the Dartmouth team demonstrated that Id4 expression correlates with
survival of glioblastoma patients and inversely correlates with MMP2 expression.
A study from Massachusetts General Hospital (MGH) Cancer Center researchers — the first to examine the effects of combined radiation and chemotherapy on the healthy brain
tissue of glioblastoma patients — reveals not only specific structural changes within patients» brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased.
The NYGC and its founding member institutions are conducting additional studies involving Watson to help accelerate the discovery of potentially actionable sequence variants in various types of cancer, including an ongoing study that involves DNA and RNA from a larger
cohort of glioblastoma patients, and a study of 200 patients with different types of cancer.
The fusion of these two genes was observed in just three percent of tumors studied, so any therapy based on this particular genetic aberration would apply to only a small
subset of glioblastoma patients.
Despite recent advances in understanding this disease, the median
survival of glioblastoma patients is only 15 months, and survival statistics have not significantly improved over the past three decades.
«Study reveals effects of chemoradiation in brains
of glioblastoma patients: Reduced grey matter volume, enlargement of ventricular space appear to be early, progressive.»